Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese outpatient with hypercholesterolemia.~* Females must be non-reproductive potential or agree to remain abstinent or use (or partner use) two acceptable methods of birth control from date of signed informed consent to the 14 days after the last dose of study drug~* Agree to maintain a stable diet that is consistent with the Japan Atherosclerosis Society Guideline 2012 (JAS2012) for prevention of atherosclerotic cardiovascular diseases for the duration of the study~Exclusion Criteria:~* Uncontrolled hypertension~* Type 1 or uncontrolled type 2 diabetes mellitus (treated or untreated)~* History of coronary artery disease (CAD) Homozygous familial hypercholesterolemia or has undergone LDL apheresis~* Had a gastrointestinal tract bypass, or other significant intestinal malabsorption~* History of cancer within the past 5 years except for successfully treated dermatological basal cell or squamous cell carcinoma or in situ cervical cancer~* Human immunodeficiency virus (HIV) positive~* History of drug/ alcohol abuse within the past 5 years or psychiatric illness not adequately controlled and stable on pharmacotherapy~* Consumes more than 25 g of alcohol per day~* Consumes more than 1L of grapefruit juice per day~* Currently following an excessive weight reduction diet~* Engaging in a vigorous exercise regimen (e.g.; marathon training, body building training etc.) or intends to start training during the study~* Hypersensitivity or intolerance to ezetimibe or atorvastatin~* History of myopathy or rhabdomyolysis with ezetimibe or any statin~* Pregnant or lactating~* Taking any other investigational drugs and/or has taken any investigational drugs within 30 days

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): 1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
- Atorvastatin 10 mg (Type: ACTIVE_COMPARATOR): 1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
- Atorvastatin 20 mg (Type: ACTIVE_COMPARATOR): 2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
- Ezetimibe 10 mg + Atorvastatin 10 mg (Type: EXPERIMENTAL): 1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
- Ezetimibe 10 mg + Atorvastatin 20 mg (Type: EXPERIMENTAL): 1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).